$JNCE & $GMED M&A Case

#JounceTherapeutics, Inc. and #RedxPharma announced an all-share merger.
$JNCE shareholders will own approximately 37% in the new Co.
#Investors suspect that the pricing terms of the $JNCE & $REDX M&A deal are #unfair.
On February 2023, cancer treatment-focused Jounce Therapeutics, Inc. (JNCE) and British pharmaceutical company Redx Pharma (REDX)  announced their plans for an all-share merger, which will result in the formation of a new entity known as Redx Inc. and its leadership will be headed by current Redx CEO Lisa Anson.
Under the terms of the merger agreement, Redx shareholders will receive 0.2105 Jounce shares for each Redx share. However, if Jounce approves the reverse stock split, the exchange rate will be adjusted to 0.0421 Jounce shares for each Redx share. 
After the deal is completed, which is projected to take place in the second quarter, $REDX shareholders are expected to own approximately 63% of Redx Inc., while $JNCE shareholders will own approximately 37%.
Investors of #Jounce may have reasons to suspect that the pricing terms of the M&A transaction are unfair and that the Company BoD breached fiduciary duties to shareholders.

Case Status

Attorney Investigation

Alleged Offence

Mismanagement,

Financial Misrepresentation,

Failure to Disclose,

Malpractice,

Negligence,

Breach of Fiduciary duty,

Omissions

Suspected Party

Directors,

Management,

Shareholder,

Investment Bank,

Service Provider

Security Type

Stocks

Trade Direction

Long

Shock Event Date

09 March 2023

$JNCE & $GMED M&A Case

Collecting participants…